Expert Interviews

Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.

Experts discuss how microsatellite-stable (MSS) status in this case affects the expected benefit of pembrolizumab and whether its continued use beyond progression in combination with other agents would be considered.

Adding HIPEC to CRS did not show any added benefit but has shown increased toxicities in patients with colorectal peritoneal metastasis.

Multidisciplinary care is important for all cancer care, specifically bone marrow transplant, stated Nina Wagner-Johnston, MD.

Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.

Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.

“Recognizing that we could follow immunotherapy with a bone marrow transplant safely was quite important,” Nina Wagner-Johnston, MD, stated.

Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.

Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.

Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Panelists discuss how second-line treatments for gastric adenocarcinoma provide survival advantages, improved quality of life, and opportunities for personalized therapy based on molecular profiling and prior treatment response.

Panelists discuss how multidisciplinary strategies incorporating chemotherapy, targeted agents, and immunotherapy are strategically sequenced to optimize outcomes for patients with advanced metastatic gastric adenocarcinoma.

Panelists discuss how multidisciplinary approaches, molecular profiling, and recent advances in targeted therapies and immunotherapy have transformed the management landscape for patients with metastatic gastric adenocarcinoma.

Panelists discuss how they incorporate nivolumab into clinical practice, highlighting specific patient characteristics, biomarkers, and disease features that predict favorable responses to this immunotherapy agent.

Panelists discuss how recent clinical trials have revolutionized treatment paradigms for gastrointestinal cancers, shaping evidence-based approaches that optimize patient outcomes through targeted therapies, immunotherapies, and multimodal treatment strategies.

Panelists discuss how the BESPOKE study’s innovative design, carefully selected efficacy end points, and rigorous methodological approach aim to evaluate personalized therapeutic interventions with unprecedented precision.

Panelists discuss how circulating tumor DNA (ctDNA) serves as a promising biomarker for early detection, treatment monitoring, and recurrence surveillance in patients with colorectal cancer (CRC).

Panelists discuss that when selecting a chimeric antigen receptor T-cell (CAR T) product for a patient with an aggressive clinical course and eligibility for cellular therapy, key considerations include urgency, toxicity risks, and efficacy. Factors such as time to manufacture, cytokine release syndrome/immune effector cell–associated neurotoxicity syndrome rates, long-term remission data, and antigen specificity guide decision-making.

Panelists discuss how PSMA PET imaging utilizes various tracers, each with distinct properties influencing image quality and diagnostic accuracy. Fluciclovine F18 (Axumin) is primarily used for detecting recurrent prostate cancer, offering moderate sensitivity but lower specificity compared with PSMA-targeted agents. Gallium Ga 68 gozetotide (Illuccix) provides high sensitivity and specificity for prostate cancer lesions; however, its shorter half-life and limited availability may restrict widespread use. Piflufolastat F18 (Pylarify) combines the benefits of F18’s longer half-life with high image resolution, enhancing detection accuracy. Similarly, flotufolastat F18 (Posluma) leverages F18’s favorable imaging characteristics, offering high-quality images and reliable lesion detection.